Judges in the Indiana Court of Appeals issued their Opinion in the case of Neptune Generics, LLC, and Fresenius Kabi USA, LLC (collectively
The ‘209 Patent “relates to administering folic acid and a methylmalonic acid (“MMA”) lowering agent, such as vitamin B12, before administering pemetrexed disodium, a chemotherapy agent, in order to reduce the toxic effects of a pemetrexed, an antifolate.” There were three petitions for IPR relating to the ‘209 Patent for obviousness over various patents, patent applications, and articles. In each IPR, the Board found that the claims were not unpatentable for obviousness.
According to the Opinion, the Board found that it was known that pretreatment with folic acid reduces the toxicity relating to the administration of an antifolate, but there was not a reason to pretreat with Vitamin B12 in addition to folic acid before administering pemetrexed for cancer treatment. Further, the FDA, along with others, were skeptical of the treatment that supported their decision for nonobviousness.
The Court of Appeals agreed with the Board’s analysis that the prior art provides a motivation to pretreat with folate, but there was not a motivation to administer an MMA lowering agent in addition to folic acid. According to the Opinion, the FDA’s concerns regarding the treatment were enough to support a conclusion of nonobviousness. While Petitioners argued the claims were not directed to patentable subject matter, the Court of Appeals found the issue improperly raised. The Court of Appeals affirmed the Board’s decision that the claims were not unpatentable for obviousness.